Use of QTRAC Technique to Measure Axonal Excitability in Anti-MAG Neuropathy
NCT ID: NCT02468596
Last Updated: 2023-02-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
6 participants
INTERVENTIONAL
2014-11-30
2022-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Because of its high sensitivity to small changes in axonal excitability, QTRAC may help improve the follow-up of patients suffering from peripheral neuropathy caused by anti-myelin-associated-glycoprotein antibodies (anti-MAG neuropathy), as axonal excitability is early affected in this disease.
The main aim of the study is to compare QTRAC results in anti-MAG neuropathy patients, with QTRAC results in healthy persons (matched for sex and age).
A secondary aim is to determine whether or not the disease's clinical severity (measured by quantitative clinical scores) is correlated with the results of the QTRAC and could be predicted by a model based on the several parameters measured in the QTRAC exploration.
100 anti-MAG neuropathy patients will undergo a QTRAC exploration and a thorough neurological examination with clinical scoring. The results will be compared with data (matched by sex and age) from the reference database on healthy subjects, that is provided with the QTRAC software.
The investigators expect to prove that QTRAC results are modified in anti-MAG neuropathy patients, and that the clinical severity of the disease can be predicted by a combination of QTRAC-measured parameters.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neurostimulation and Electromyographic Assessment of the TetraGraph (NEAT) In Patients (NEAT-3)
NCT02241304
Evaluation of Muscle Strength by Transcutaneous Electrical Stimulation
NCT03270163
Neuromuscular Monitoring in Children (6 Months - 2 Years) With Electromyography and Acceleromyography
NCT06409260
Neurostimulation and Electromyographs Assessment of th TetraGraph in Healthy (Volunteers
NCT02630576
Micro-EMG: A Novel Multi-electrode System for Intramuscular Imaging
NCT05713474
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients
Patients suffering from anti-MAG neuropathy
QTRAC assessment
Computerized analysis of the muscular response of musculus abductor pollicis brevis, to series of electrical stimulations of the median nerve
Clinical assessment of peripheral nerve function
Clinometric assessment using RT-MRC, Martin vigirometer, RT-mISS, T25W, 9 hole peg test, and ataxia scale
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
QTRAC assessment
Computerized analysis of the muscular response of musculus abductor pollicis brevis, to series of electrical stimulations of the median nerve
Clinical assessment of peripheral nerve function
Clinometric assessment using RT-MRC, Martin vigirometer, RT-mISS, T25W, 9 hole peg test, and ataxia scale
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation Ophtalmologique Adolphe de Rothschild
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service de Neurologie Hôpital Pellegrin
Bordeaux, , France
Service de Neurologie Hôpital Henry Mondor
Créteil, , France
Département de Neurologie Hôpital Roger Salengro
Lille, , France
service de neurologie, CHU Limoges
Limoges, , France
Service ENMG et pathologies Neuro Musculaires, Hôpital Neurologique Pierre Wertheimer
Lyon, , France
Laboratoire des explorations fonctionnelles, Hôtel Dieu
Nantes, , France
Service de Neurologie, Fondation Ophtalmologique Adolphe de Rothschild
Paris, , France
Service de Neurologie CHU St Etienne
Saint-Etienne, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AGN_2014-20
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.